Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of “Reduce” from Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has been assigned an average recommendation of “Reduce” from the eight brokerages that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $24.00.

AMPH has been the topic of a number of analyst reports. Weiss Ratings cut Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Barclays decreased their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock opened at $21.78 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The business’s 50 day simple moving average is $19.89 and its two-hundred day simple moving average is $22.87. The stock has a market capitalization of $960.28 million, a P/E ratio of 13.12, a price-to-earnings-growth ratio of 4.14 and a beta of 0.91. Amphastar Pharmaceuticals has a one year low of $16.65 and a one year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million during the quarter, compared to analysts’ expectations of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. Analysts forecast that Amphastar Pharmaceuticals will post 2.41 EPS for the current year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $26,000. Quarry LP bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $32,000. Farther Finance Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after buying an additional 437 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock worth $45,000 after buying an additional 462 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Amphastar Pharmaceuticals by 24.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after buying an additional 435 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.